


CLAIMS

1. A compound of the formula



5 wherein:

each X is independently CH₂, C(O), N, O, S, S(O), S(O)₂, or is a bond; and

each of R₁ to R₅ is independently a bond or is selected from the group consisting of:

hydrogen;

halogen;

10 azide;

an R group defined as C1 to C8 alkyl or alkenyl, aryl or heteroaryl optionally further substituted by:

an alkoxy, aryl, heteroaryl or aryloxy;

-COOH, -S(O)₂OH;

15 -S(O)₂OH, -S(O)OH, -S(O)R, S(O)₂R, -S(O)₂NH₂, -S(O)₂OR, -S(O)OR;


-C(O)R;

a heterocyclic group further substituted by:

an alkyl, aryl, -CH₂NHC(O)R, -CH₂N(C(O)R)₂, or -CH₂OR;

a substructure of the following formula:

20



wherein at least one, but not more than two of R₇ to R₁₁ is independently a structure according to formula I;

wherein:

25 each Y is independently a bond, H, R or -C(O)R as defined above; and up to but no more than one of each of R₇ to R₁₁ is independently a structure according to formula II, or each of R₇ to R₁₁ is independently absent; or

each R₁ to R₅ is connected to a different R₁ to R₅ to form a fused bicyclic structure; with the provisos that:

when R₁ is -CH₃, -S(O)₂OH or -H at least one of R₂ to R₅ is not -H or -S(O)₂OH; and

5 when a substructure of type II is not present and none of R₁-R₅ form an anhydro bridge, no more than two of R₁-R₅ are -S(O)₂OH and the stereochemistry of I is not gluco or galacto.

2. A compound according to claim 1, wherein said compound is PG2024, PG2037, PG2173, PG2198, as hereinbefore described.

10 3. A compound according to claim 1, wherein said compound is any one of the compounds of Tables 1-4 of the description.

4. A pharmaceutical or veterinary composition for the prevention or treatment in a mammalian subject of a disorder resulting from angiogenesis, metastasis, inflammation, coagulation, thrombosis, and/or microbial infection, which composition comprises at least one 15 compound according to claim 1 together with a pharmaceutically or veterinarily acceptable carrier or diluent for said at least one compound.

5. The composition according to claim 4 which further includes a pharmaceutically or veterinarily acceptable excipient, buffer, stabiliser, isotonicising agent, preservative or antioxidant.

20 6. The composition according to claim 4, wherein said compound is present therein as an ester, a free acid or base, a hydrate, or a prodrug.

7. The composition according to claim 4, wherein one or more sulfate groups of said compound has been substituted for an alternate charged group.

25 8. The composition according to claim 7, wherein said alternate charged group is a phosphate, carboxylate or tetrazolyl anion.

9. Use of a compound according to claim 1 in the manufacture of a medicament for the prevention or treatment in a mammalian subject of a disorder resulting from angiogenesis, metastasis, inflammation, coagulation, thrombosis, and/or microbial infection.

10. The use according to claim 9, wherein said mammalian subject is a human subject.

30 11. A method for the prevention or treatment in a mammalian subject of a disorder resulting from angiogenesis, metastasis, inflammation, coagulation, thrombosis, and/or microbial infection, which method comprises administering to the subject an effective amount

of at least one compound according to claim 1, or a composition comprising said at least one compound.

12. The method according to claim 11 wherein said mammalian subject is a human subject.

13. The method according to claim 11, wherein said disorder resulting from angiogenesis is
5 a proliferative retinopathy or angiogenesis resulting from the growth of a solid tumour.

14. The method according to claim 11, wherein said disorder resulting from inflammation is rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, allograft rejection or chronic asthma.

15. The method according to claim 11, wherein said disorder resulting from coagulation and/or thrombosis is deep venous thrombosis, pulmonary embolism, thrombotic stroke, peripheral arterial thrombosis, unstable angina or myocardial infarction.
10

16. The method according to claim 11, wherein said disorder resulting from viral infection is Herpes Simplex.